Abstract
The Gly388Arg polymorphism in the fibroblast growth factor receptor 4 (FGFR4) gene has been reported to influence prognosis in a wide variety of cancer types. To determine whether Gly388Arg is a marker for lung cancer prognosis, we genotyped 619 lung cancer patients with incident disease and examined the relationship between genotype and overall survival. While we employed a comprehensive set of statistical tests, including those sensitive to the detection of differences in early survival, our data provide little evidence to support the tenet that the FGFR4 Gly388Arg polymorphism is a clinically useful marker for lung cancer prognosis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Substitution*
-
Arginine
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / therapy
-
Carcinoma, Small Cell / genetics
-
Carcinoma, Small Cell / pathology
-
Carcinoma, Small Cell / therapy
-
Combined Modality Therapy
-
Glycine
-
Humans
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Lung Neoplasms / therapy
-
Middle Aged
-
Neoplasm Staging / mortality
-
Polymorphism, Single Nucleotide
-
Prognosis
-
Receptor, Fibroblast Growth Factor, Type 4 / genetics*
-
Survival Analysis
Substances
-
Arginine
-
FGFR4 protein, human
-
Receptor, Fibroblast Growth Factor, Type 4
-
Glycine